Moderna and Recordati Form Strategic Alliance to Commercialize mRNA Therapy for Propionic Acidemia

On January 29, 2026, Moderna announced a strategic collaboration agreement with Recordati to advance Moderna’s mRNA-3927, an investigational product for treating propionic acidemia (PA), through the final stages of clinical development as well as global commercialization upon approval. This partnership arrives at a historic moment for the Italian pharma company, which celebrates its centennial anniversary in 2026, marking a century of evolution from a small family pharmacy to a global contender in the field of rare disease therapeutics. 

Under the terms of the deal, Moderna will retain responsibility for leading the ongoing clinical development and manufacturing of the therapy, while Recordati will leverage its established infrastructure to lead global commercialization efforts upon regulatory approval.

Understanding Propionic Acidemia

Propionic acidemia (PA) is an ultra-rare, life-threatening, autosomal recessive metabolic disorder that affects approximately 1 in 100,000 to 150,000 individuals worldwide. The disease is fundamentally a biochemical blockade caused by a deficiency in propionyl-CoA carboxylase (PCC), a critical mitochondrial enzyme composed of alpha (PCCA) and beta (PCCB) subunits. In healthy individuals, this enzyme breaks down certain biomolecules including valine, odd-chain fatty acids, methionine, isoleucine and threonine (thus giving the mnemonic “VOMIT”). However, in patients with PA, the enzyme is non-functional or absent, leading to a toxic accumulation of propionyl-CoA and other hazardous metabolites like 2-methylcitrate and 3-hydroxypropionate.

The clinical presentation of PA is severe and multisystemic. Neonatal onset in infants shortly after birth (often 24–72 hours) is common, characterized by “metabolic strokes” involving vomiting, lethargy, seizures, and hyperammonemia (abnormally elevated levels of ammonia in the blood) that can rapidly progress to coma and death if untreated. 

Beyond the acute crises, known as metabolic decompensation events (MDEs), the chronic toxicity of the disease exerts a heavy toll on the body. Long-term complications often include cardiomyopathy, a leading cause of mortality in older patients, as well as recurrent pancreatitis and intellectual disability. 

Currently, there is no therapy that addresses the root cause. Disease management remains palliative, relying on a severely restrictive low-protein diet and medical foods to limit the intake of PA-precursor amino acids. This dietary regimen is often described by families as a “constant state of hunger” and anxiety, where even minor illnesses can trigger life-threatening crises.

Restoring the Metabolic Pathway with mRNA-3927

mRNA-3927 represents a paradigm shift in treating metabolic errors. Unlike traditional small molecule drugs that might manage symptoms, mRNA-3927 is an intracellular enzyme replacement therapy which holds disease-modifying potential. The therapeutic consists of two distinct mRNAs encoding the normal human PCCA and PCCB subunits, encapsulated within Moderna’s proprietary lipid nanoparticles (LNPs). These LNPs serve a dual purpose: they protect the fragile mRNA cargo from degradation in the bloodstream and facilitate its uptake into liver cells (hepatocytes).

Once administered via intravenous infusion, the LNPs deliver the mRNA payload directly into the cytoplasm of the liver cells. There, the patient’s own cellular machinery translates the mRNA into functional PCCA and PCCB proteins, which assemble inside the mitochondria to form an active PCC enzyme. This effectively turns the patient’s liver into a factory for the missing enzyme, restoring the metabolic pathway and enabling the body to process propionic acid normally.

According to interim data from the ongoing Phase 1/2 PARAMOUNT study, mRNA-3927 is not only safe, but also capable of reducing the frequency of MDEs and improving quality of life. More importantly, this therapy avoids the risks of permanent genomic integration associated with some viral gene therapies, offering a “tunable” treatment where dosage adjustment according to patients’ needs is possible.

Moderna’s Strategic Rationale and Financial Benefits

For Moderna, the decision to partner with Recordati reflects a strategic prioritization of patient access over vertical integration. In a recent interview, Moderna CEO Stéphane Bancel explained that while Moderna excels at the science of mRNA development and manufacturing, the commercialization of rare disease therapies requires a highly specialized, high-touch support network that takes decades to build. “Recordati brings deep rare disease commercial expertise… that will help us accelerate the benefit of mRNA-3927 upon approval,” Bancel noted.

Under the terms of the agreement, Moderna will receive an upfront payment of $50 million and up to a further $110 million in near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales of mRNA3927 once it hits the market. This capital infusion supports Moderna’s broader pipeline while ensuring mRNA-3927 is in the hands of a partner with a dedicated metabolic sales force.

Recordati’s Centennial: A New Chapter in Metabolic Medicine

For Recordati, securing this asset is a fitting way to commence its centennial year. Founded in 1926 in Correggio, Italy, the company has spent the last century evolving into a major European pharmaceutical player with a specific focus on rare diseases through its Recordati Rare Diseases unit. Rob Koremans, Recordati’s CEO, highlighted that this deal reinforces their “heritage in the metabolic field” and aligns perfectly with their mission to address unmet medical needs. By adding a late-stage, potentially disease-modifying asset to their portfolio, the Milan-based pharma company strengthens its position as a preferred partner for biotechs looking to navigate the complex European and global rare disease markets.

Broader Implications for Rare Disease Development 

The implications of this partnership extend far beyond propionic acidemia. First, it serves as a critical validation of LNP technology for chronic, repeated dosing. While mRNA vaccines (like those for COVID-19) are administered acutely, mRNA-3927 requires regular infusions over a patient’s lifetime. Success here proves that LNPs can be used safely as a chronic maintenance therapy without eliciting neutralizing antibodies that render the drug ineffective—a major hurdle for many biologic therapies.

Moreover, this program validates the “Liver Depot” concept, where the liver acts as a bio-reactor to produce therapeutic proteins for systemic benefit. If mRNA-3927 succeeds, it significantly de-risks Moderna’s other programs targeting rare metabolic disorders, such as mRNA-3705 for methylmalonic acidemia (MMA) and potential future candidates for glycogen storage disease (GSD). It suggests a replicable platform where only the mRNA sequence needs to be swapped to treat different enzyme deficiencies.

Furthermore, the deal signals a shift in the biotech business model for rare diseases. Rather than the “go-it-alone” strategy that characterized the sector’s boom years, companies are increasingly adopting hybrid models—developing the science in-house while partnering for the “last mile” of commercialization. This efficiency ensures that innovation is not bottlenecked by the need to build global sales infrastructure for every single indication.

As both companies move toward the pivotal data readout expected in 2026, the stakes are high. For patients with PA, this represents the first tangible hope for a life free from the constant threat of metabolic crisis. For the industry, it is a test case for the durability of mRNA therapeutics in chronic disease. “We are proud to partner with Recordati in a joint mission to improve the lives of people living with propionic acidemia,” Bancel concluded, setting the stage for a potentially transformative year in rare disease medicine.

Author

Richard Chau